Overview
- A securities class action was filed against Regeneron and certain officers alleging false or misleading statements about the Phase III Fianlimab‑Libtayo study and covering purchases from August 1, 2025 through May 15, 2026.
- The complaints say Regeneron used flawed preliminary statistical assumptions, failed to show meaningful clinical differentiation in the active arm, and thus overstated the study’s chance of meeting its primary endpoint.
- Multiple shareholder‑rights firms have publicized the suit and are soliciting investors to join and seek lead‑plaintiff status, and these firms say investors must apply by September 14, 2026 to be considered for that role.
- The class has not been certified and plaintiffs assert damages occurred when later disclosures contradicted earlier statements, so any collective recovery will depend on court appointment of a lead plaintiff and later proof of material misstatements and loss causation.
- If the case moves forward, it could affect investor recoveries and corporate disclosure practices for drug trials because it centers on how companies report trial design choices, statistical assumptions, and interim results to the market.